Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication OptionPRNewsWire • 09/06/22
Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property LitigationsPRNewsWire • 08/01/22
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/27/22
Boston Scientific Narrowly Tops Second-Quarter Expectations; Shares SurgeInvestors Business Daily • 07/27/22
Boston Scientific tops profit and sales expectations, but trims full-year outlookMarket Watch • 07/27/22
Boston Scientific Announces Conference Call Discussing Second Quarter 2022 ResultsPRNewsWire • 06/29/22
Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., LtdPRNewsWire • 06/15/22